Aids

• 

  Publication Venue For

  • Longitudinal HIV care outcomes by gender identity in the United States..  36:1841-1849. 2022
  • Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015..  35:1229-1239. 2021
  • Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel: Erratum.  34:2161-2163. 2020
  • Impact of immediate initiation of antiretroviral therapy on HIV patient satisfaction..  34:267-276. 2020
  • Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa.  30:2341-2350. 2016
  • Interventions to improve adherence to antiretroviral therapy.  28:S187-S204. 2014
  • Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy..  27:1827-1829. 2013
  • Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero.  26:2053-2058. 2012
  • Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics..  24:2687-2696. 2010
  • Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort..  23:631-636. 2009
  • Exploring the role of economic empowerment in HIV prevention..  22 Suppl 4:S57-S71. 2008
  • A combined microfinance and training intervention can reduce HIV risk behaviour in young female participants..  22:1659-1665. 2008
  • Systematic review exploring time trends in the association between educational attainment and risk of HIV infection in sub-Saharan Africa..  22:403-414. 2008
  • Chronic kidney disease in HIV infection: an urban epidemic..  21:2101-2103. 2007
  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years..  21:1273-1281. 2007
  • Efavirenz: innocent bystander or direct nephrotoxin?.  21:1393. 2007
  • Relapse of HIV-associated nephropathy after discontinuing highly active antiretroviral therapy..  21:263-264. 2007
  • Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia..  20:2207-2215. 2006
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults..  20:2051-2064. 2006
  • HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers..  20:1481-1489. 2006
  • Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality..  20:561-565. 2006
  • Dual tropism of HIV-1 envelopes derived from renal tubular epithelial cells of patients with HIV-associated nephropathy..  20:621-624. 2006
  • HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN..  19:1975-1980. 2005
  • High HIV, hepatitis C and sexual risks among drug-using men who have sex with men in northern Thailand..  19:1535-1540. 2005
  • Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia..  19:1309-1315. 2005
  • HIV-1 co/super-infection in intravenous drug users.  18:1413-1421. 2004
  • Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12..  18:1203-1206. 2004
  • Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen..  18:991-1001. 2004
  • Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients..  18:199-204. 2004
  • The cost of HIV/AIDS to businesses in southern Africa..  18:317-324. 2004
  • A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV..  17:2331-2336. 2003
  • Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection..  17:2025-2033. 2003
  • A tailored minimal self-help intervention to promote condom use in young women: results from a randomized trial..  17:1547-1556. 2003
  • Sexual behavior of HIV discordant couples after HIV counseling and testing..  17:733-740. 2003
  • Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions..  16:2342-2344. 2002
  • HIV-1 dynamics in haemodialysis patients..  16:1301-1303. 2002
  • Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques..  16:829-838. 2002
  • Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels..  16:407-412. 2002
  • Plasma carnitine in HIV-associated neuropathy..  15:2207-2208. 2001
  • Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults..  15:1369-1377. 2001
  • Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model..  15:621-627. 2001
  • Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages)..  14:2937-2939. 2000
  • Effectiveness of HIV prevention interventions in developing countries..  14 Suppl 2:S68-S84. 2000
  • Enriching the mix: incorporating structural factors into HIV prevention..  14 Suppl 1:S1-S2. 2000
  • Structural interventions in public health..  14 Suppl 1:S11-S21. 2000
  • Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia..  14:75-83. 2000
  • The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration..  13:487-494. 1999
  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group..  12:2407-2415. 1998
  • Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS..  12:1983-1990. 1998
  • Taste and smell complaints in HIV-infected patients..  12:1667-1674. 1998
  • Pediatric AIDS prognosis using somatic growth velocity..  12:1361-1369. 1998
  • Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative..  12:1291-1300. 1998
  • Inhibition of interleukin-2 and interferon-gamma by an HIV-1 Nef-encoded synthetic peptide..  12:820-823. 1998
  • Decreasing incidence of HIV and sexually transmitted diseases in young Thai men: evidence for success of the HIV/AIDS control and prevention program..  12:F29-F36. 1998
  • A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS..  12:269-277. 1998
  • The risks and benefits of childhood bacille Calmette-Guérin immunization among adults with AIDS. International MAC study groups..  11:669-672. 1997
  • Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials..  11:477-483. 1997
  • Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group..  11:169-175. 1997
  • The antibody response in HIV-1 infection..  11 Suppl A:S87-S98. 1997
  • CD4+ memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children..  10:1477-1484. 1996
  • HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group..  10:859-865. 1996
  • Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy..  10:263-268. 1996
  • The epidemiology of HIV and syphilis among male commercial sex workers in northern Thailand [9].  10:113. 1996
  • The role of host genetics in the natural history of HIV-1 infection: the needles in the haystack..  10 Suppl A:S59-S67. 1996
  • Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand..  9:1079-1083. 1995
  • The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine..  9:727-734. 1995
  • The epidemiology of HIV and syphilis among male commercial sex workers in northern Thailand..  9:517-521. 1995
  • Same-sex behavior, sexually transmitted diseases and HIV risks among young northern Thai men..  9:171-176. 1995
  • Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact..  9 Suppl A:S259-S272. 1995
  • Origins and diversity of human immunodeficiency viruses.  8. 1994
  • HIV-1 infection in the lymphoid organs..  7 Suppl 2:S53-S58. 1993
  • Intestinal parasites and HIV infection in Tanzanian children with chronic diarrhea..  7:213-221. 1993
  • Foreword.  5. 1991
  • Vaccines and immunology: Overview.  4. 1990
  • Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS..  4:519-521. 1990
  • AIDS 1990. Vaccines and immunology: overview..  4 Suppl 1:S127-S128. 1990
  • HIV antibodies and vaccine design..  3 Suppl 1:S111-S118. 1989
  • Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000..  15:W1-W25. 2001
  • Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group..  14:1365-1374. 2000
  • Explaining continued high HIV prevalence in South Africa: socioeconomic factors, HIV incidence and sexual behaviour change among a rural cohort, 2001-2004. 2007
  • Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. 2001